Novavax’s stock declined -12% over the last twenty-one trading days (about one month), compared to the broader market (S&P500) which remained roughly flat.
and U.K, it could potentially be used as a booster in other markets. will likely miss out on initial booster sales in markets such as the U.S. While Novavax - which is in the process of wrapping up its filing for emergency use in the U.S. That being said, Covid-19 vaccine demand could hold up as governments worldwide look to protect populations against waning immunity from initial doses. FDA recently granted emergency use authorization for oral Covid therapeutics from Merck and Pfizer last week, further reducing concerns about the impact of the recent virus surge. While there has actually been some positive news for Novavax, which indicated that its Covid-19 vaccine showed positive results against the omicron variant of the novel coronavirus, there have been separate studies done in South Africa and the U.K, which indicate that the variant likely isn’t as concerning as initially feared.
(Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty ImagesĬovid-19 vaccine developer Novavax’s stock (NASDAQ: NVAX) declined by about 9% over the last week (five trading days), compared to the S&P 500 which remains up by about 1% over the same period. coronavirus vaccine seen in front of Novavax US vaccine development company logo. UKRAINE - 4: In this photo illustration a medical syringe and a vial depicting fake.
0 kommentar(er)
